Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Werewolf Therapeutics, Inc. (Nasdaq: HOWL), a biopharmaceutical innovator specializing in immune-stimulating cancer therapeutics, announced its participation in the SVB Leerink Global Healthcare Conference from February 14-18, 2022. The company’s CEO, Daniel J. Hicklin, will present on February 16 at 3:40PM EDT. A webcast link will be provided, and a replay will be available for 30 days post-presentation. Werewolf's proprietary PREDATOR™ platform focuses on creating conditionally activated molecules, including its leading candidates WTX-124 and WTX-330, targeting solid tumors.

CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present at the SVB Leerink Global Healthcare Conference taking place virtually from February 14-18, 2022.

Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, will provide an overview of the company at 3:40PM EDT on February 16. A link to the webcast will be available at https://investors.werewolftx.com/news-and-events/events.   An archived replay will be available for approximately 30 days following the presentation.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

To learn more visit www.werewolftx.com.

Investor Contact:
Jonathan M. Nugent
Stern IR
212.698.8698
jonathan.nugent@sternir.com

Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com

Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com

FAQ

What is Werewolf Therapeutics presenting at the SVB Leerink Global Healthcare Conference?

Werewolf Therapeutics will present an overview of its innovative cancer therapeutics at the conference.

When is Werewolf Therapeutics' presentation at the SVB Leerink Global Healthcare Conference?

The presentation is scheduled for February 16, 2022, at 3:40PM EDT.

Where can I watch the Werewolf Therapeutics presentation?

The presentation will be available via a webcast link provided by the company.

What are the key products being developed by Werewolf Therapeutics?

Werewolf is developing WTX-124 and WTX-330, which are designed to treat solid tumors.

What technology does Werewolf Therapeutics use for its drug development?

The company uses its proprietary PREDATOR™ platform to create conditionally activated therapeutics.

How long will the archived replay of Werewolf Therapeutics' presentation be available?

The archived replay will be available for approximately 30 days after the presentation.